Collegium Pharmaceutical: Pain Cash Flows Are Funding An ADHD Re-Rating

Collegium Pharmaceutical (COLL) is transitioning from a pain-management roll-up to a CNS platform, leveraging stable pain cash flows to fuel ADHD franchise growth. The AZSTARYS acquisition, funded with $350M cash and $300M debt, is expected to deliver $60–70M revenue in 2026 and $50M+ annual synergies within 12 months. COLL's 2026 guidance is $865–895M in revenue and $475–500M adjusted EBITDA, with a 55% margin, reflecting only partial-year AZSTARYS contribution and early synergies. Despite double-digit ADHD growth and immediate EBITDA accretion, COLL trades at a deep EV/EBITDA discount (3.47x), as the market underappreciates its evolving growth profile.

I'm bullish on Collegium Pharmaceutical ( COLL ) because I believe the market still views the company as a mature pain-management roll-up while its commercial profile is quickly shifting toward a longer-duration ADHD franchise. A key This article was written by Equity Eagle 1.19K Followers Follow I have a strong inclination towards high-growth companies, often treading in sectors poised for exponential expansion. My expertise lies in understanding and investing in disruptive technologies and forward-thinking enterprises. My approach is a mix of fundamental analysis and future trend prediction. I believe in the power of innovation to yield substantial returns and aim to provide insightful analysis on such companies here on SeekingAlpha.